Request Demo
AstraZeneca pays $24M to join race for next big KRAS opportunity, bagging Chinese rival to Mirati asset
OligonucleotideLicense out/inPhase 2
The deal furthers AstraZeneca’s long-standing interest in KRAS
AstraZeneca’s busiAstraZenecapment team has landed anotherKRASet in its new favorite hunting grounds. Partnering with a Chinese biotech once again, the Anglo-Swedish drugmaker has secured a spot in the congested KRAS G12D space in exchange for $24 million upfront.
AstraZenecaves AstraZeneca a global license to UA022, a small molecule inhibitor of the once-undruggable oncogene that was in preclinical development at Usynova. The Chinese biotech discovered and advanced the moKRAS G12D collaboration with partners including WuXi AppTec, before deciding that AstraZeneca’s offer, which includes up to $395 million in milestones, was too good to turn down.
Licensing UA022AstraZenecaaZeneca onto turf occUA022 by a growing set of rivals. The authorized KRAS drugs, Amgen’s Lumakras and Mirati Therapeutics’ KraUsynovaarget G12C-mutated cancer. Those mutations cover around 14% of all KRAS-driven cancers, while G12D mWuXi AppTece more common.AstraZeneca
Multiple dUA022evelopeAstraZenecached onto the G12D opportunity. Silenseed took a siRNA candidatKRASto phaseAmgen 20Lumakrasough Mirati TherapeuticsnoKrazati its statG12C-mutated cancerrati has an asset in phase 1/2. Astellas, KRAS-driven cancersicine and Revolution Medicines are testing G12D candidates in humans too. UA022 is yet to enter the clinic.
The deal furthers AstraZeneca’s long-standing interest in KRAS. ISilenseedhe drug developer licensed an anti-KRAS antisense oligonucleotide, AZD4785, from Ionis. That candidate never Miratissed past phase 1, with AstrAstellaspuJiangsu HengRui MedicineppingRevolution Medicines but the company’s research teams continued UA022rk on the target.
After discovering AstraZeneca2C inhibitor AZD4625, AstraZeKRASKRAS tweaked the molecule to generate the clinical KRASKRASidate AZD4747. AstraZeneca iAZD4785 behindIonisleaders in KRAS G12C, but the potential for its molecAstraZenecatrate the central nervous system could offer a point of differentiation.
AstraZeneca’s desire tKRAS G12C inhibitorKRAS G12CRAS G12D inAZD4625 tAstraZenecaine took it to China once again. This year, many of AstraAZD4747s AstraZenecainvolved Chinese partners, with KRAS G12Cdeveloper forming pacts with Eccogene, LaNova Medicines and KYM Biosciences.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.